FMP
NASDAQ
75.09 USD
-1.55 (-2.06%)
Dr. James R. Porter Ph.D.
Healthcare
Biotechnology
https://www.nuvalent.com
NASDAQ
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-gener...
0001861560
US6707031075
670703107
One Broadway
857 357 7000
US
92
Jul 29, 2021
0001861560
NASDAQ
Biotechnology
Healthcare
670703107
US6707031075
US
75.09
1.36
378.14k
4.81B
-
23.095-89.39
5.76
-
-
-
-
-34.6
-
https://www.nuvalent.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.